Business
Allowance of U.S. patent covering AI-supported CNS
Allowance of U.S. patent covering AI-supported CNS.
About this update from Solvonis Therapeutics Plc
[{"type":"text","content":"\n\n23 June 2025\nSolvonis Therapeutics plc\n(\"Solvonis\" or the \"Company\")\nAllowance of U.S. patent covering AI-supported CNS discovery programme compounds\n \nSolvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, is pleased to announce that the U.S. Patent and Trademark Office (the \"USPTO\") has allowed a key patent application protecting compounds within the Company's AI-enabled CNS discovery programme.\nThe application-U.S. No. 18/838,986, titled \"Bridged Ring Compounds and Their Therapeutic Use as CNS Agents\"-received a first-action allowance with no objections or rejections. The claims cover composition of matter and methods of use for a family of novel morpholine-class compounds, originally developed by Awakn Life Sciences Corp. and now central to Solvonis' Central Nervous System (\"CNS\") library.\nAn \"allowance\" confirms that a patent will be granted, subject only to final administrative steps.\nThe CNS library, which includes multiple chemically distinct, preclinically validated series, underpins Solvonis' AI-supported drug discovery platform. The patent adds meaningful protection across novel CNS chemical space, especially in depression, stimulant use disorder and other neuropsychiatric conditions.\nThe patent, expected to be granted in the coming months, will confer U.S. exclusivity through to at least 2043, reinforcing the long-term value of Solvonis' early-stage pipeline.\nProfessor David Nutt, Chief Scientific Officer of Solvonis, commented: \"This patent strengthens the foundation of our discovery platform and provides long-term protection for a chemically distinct series of CNS-active compounds already integrated into our AI-supported programme. The favourable examination outcome reflects the novelty and robustness of the underlying chemistry, which has now been further validated through translational screening and computational analyses.\"\nAnthony Tennyson, Chief Executive Officer of Solvonis, added: \"We are delighted by this outcome, which validates the early-stage innovation acquired through Awakn and enhances the strategic value of our AI-enabled platform. This grant provides additional confidence as we advance our discovery pipeline targeting major unmet needs in neuropsychiatry.\"\n \nEnqu...